First Trust Nasdaq Pharmaceuticals ETF

In the first nine months of this year, Pfizer’s (PFE) vaccines sales grew ~7% YoY (year-over-year) to $4.7 billion from $4.4 billion.

Allergan (AGN) is set to release its Q3 2018 earnings on October 30. Analysts estimate EPS of $4.03 on revenues of $3.88 billion.

Analysts expect Pfizer’s (PFE) revenues to be ~$13.5 billion in the third quarter—which is ~2.8% growth compared to the third quarter of 2017.

Pfizer (PFE) is one of the leading healthcare companies. Pfizer stock increased 1.5% and closed at $44.57 on October 17.

Sixteen analysts currently track Eli Lilly (LLY) stock. Two analysts recommend a “strong buy,” six analysts recommend a “buy,” and eight analysts recommend a “hold.”

Pfizer (PFE) reported EPS of $0.74 on revenue of ~$13.5 billion in the second quarter, surpassing Wall Street analysts’ consensus estimate.

Allergan’s total investment in the Medical Aesthetics and Innovation Center is ~$14.7 million.

Sage Therapeutics’ (SAGE) product portfolio includes products under development for the treatment of various rare and life-threatening central nervous system disorders.

In this article, we’ll compare the valuations of Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

Eli Lilly and Company’s (LLY) new products portfolio includes new products that have been launched since 2014.

Allergan’s International Business segment reported revenue of $949 million in the second quarter.

Sage Therapeutics developed SAGE-718, which targets the NMDA Receptor.

SAGE Therapeutics’ stock price has risen nearly 111.5% in the last 12 months.

On May 30, Sage Therapeutics announced that the FDA accepted the new drug application for Brexanolone IV.

In 1Q18, Merck’s (MRK) Animal Health segment, which includes drugs and vaccines for animals, saw its revenue grow 13% YoY (year-over-year) to ~$1.1 billion from $939 million.

Allergan (AGN) surpassed Wall Street analysts’ estimates, reporting earnings per share of $3.74 on revenues of $3.7 billion during 1Q18.

Wall Street analysts expect Merck & Co.’s (MRK) top line to increase 7.1% to $10.1 billion for 1Q18, compared to revenues of $9.4 billion for 1Q17.

In 2018, stock markets, especially in the pharmaceutical sector, have seen heightened volatility.

Analysts estimate Bristol-Myers Squibb will post EPS of $0.85 and revenues of $5.2 billion for 1Q18.

Johnson & Johnson reported growth across all three of its segments: the pharmaceutical segment, the consumer health segment, and the medical devices segment.

Bristol-Myers Squibb stock has fallen ~1.6% in 1Q18, and its stock has fallen ~0.6% YTD (year-to-date) as of April 6, 2018.

Eli Lilly and Company’s (LLY) products are classified into two business segments: Human Pharmaceuticals and Animal Health.

Wall Street analysts expect Johnson & Johnson to generate EPS of $2.01 on revenues of ~$19.4 billion in 1Q18 for 9.2% growth in revenues compared to 1Q17.

In Pfizer’s (PFE) portfolio, a few of the products reported a lower sales trend due to competition from other products in the markets.

As we discussed earlier in this series, Mylan (MYL) reported revenues of $2.98 billion in 3Q17, a 2.3% decline in revenues compared to $3.06 billion in 3Q16.

Analysts’ estimates Between 4Q16 and 4Q17, Wall Street analysts expect Pfizer’s (PFE) revenue to rise ~0.8% to $13.72 billion from $13.63 billion. However, analysts expect it to fall ~0.5% to $52.6 billion in 2017 from $52.8 billion in 2016. They expect Pfizer to see EPS (earnings per share) of $0.56 in 4Q17 and $2.59 in 2017. Analysts’ ratings The above chart shows analysts’ recommendations […]

Eli Lilly and Co.’s (LLY) product portfolio includes Basaglar, Jardiance, Cyramza, Lartruvo, Taltz, Olumiant, and Trulicity.

In 3Q17, in the US and outside the US (international markets), JNJ’s pulmonary hypertension portfolio generated revenues of $357 million and $283 million, respectively.

In 3Q17, Pfizer’s (PFE) Lipitor reported revenues of $491 million, a ~16% increase on a year-over-year (or YoY) basis and ~10% growth on a quarter-over-quarter basis.

Of the 22 analysts covering Bristol-Myers Squibb, nine analysts recommend a “buy,” 11 analysts recommend a “hold,” and two analysts recommend a “sell.”

JNJ’s stock price has increased nearly 16.2% in the last 12 months and nearly 18.6% year-to-date.

Bristol-Myers Squibb’s (BMY) Immunoscience franchise includes Orencia, which is a fusion protein used for the treatment of rheumatoid arthritis and aligned problems.

Johnson & Johnson’s (JNJ) medical devices segment includes cardiovascular care, diabetes care, orthopedics, surgery, and vision care products.

Pfizer’s (PFE) Essential Health segment reported a fall in overall revenues in 2Q17, driven by the loss of exclusivity of Celebrex and Zyvox.

The products under development for the treatment of life-threatening central nervous system (or CNS) disorders in Sage Therapeutics’ (SAGE) portfolio are either based on GABA or NMDA receptor systems.

Merck’s (MRK) Animal Health segment includes drugs and vaccines for animals and has operations spread across more than 140 countries worldwide.

The Human Pharmaceuticals segment reported revenues of ~$5.0 billion during 2Q17, representing 10.9% growth compared to its 2Q16 revenues.

In 2Q17, Pfizer’s Inflectra/Remsima reported revenues of ~$94 million compared to $45 million in 2Q16.

Major developments All of Johnson & Johnson’s (JNJ) segments performed positively in 2Q17. In this part. we’ll look at some developments that occurred during the quarter. Pharmaceuticals On August 21, 2017, Johnson & Johnson presented new data for its COMPASS study, a phase III study evaluating Xarelto as a treatment for coronary and peripheral artery disease. […]

Pfizer (PFE) is one of the largest pharmaceutical companies by revenue. It reported a 2% decline in revenues, to $12.89 billion in 2Q17 from $13.15 billion in 2Q16.

In 3Q16, Johnson & Johnson’s (JNJ) top line rose 4.2% to ~$17.8 billion, driven by 4.3% operational growth in revenues.

Opdivo is a human PD-1 blocking antibody used in lung cancer and melanoma treatments. Opdivo is part of BMY’s alliance with Ono Pharmaceutical.

Analysts expect Johnson & Johnson’s (JNJ) 3Q16 revenues to rise 3.7% to $17.7 billion. The expectation comes on the back of an increase in sales of its blockbuster drugs.